SCHEMBL5074378

SCHEMBL5074378

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1ccccc1Br

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
TSHR P16473 5/20 0.39
HSD17B10 Q99714 4/20 0.39
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
CYP3A4 P08684 3/20 0.39
HPGD P15428 3/20 0.39
PDE4B Q07343 2/20 0.39
HDAC1 Q13547 1/20 0.39
CNR2 P34972 1/20 0.39
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
NFKB1 P19838 1/20 0.37
CYP2C19 P33261 1/20 0.37
TP53 P04637 1/20 0.36
LMNA P02545 1/20 0.36
BLM P54132 1/20 0.36
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135923 0.97 C5AR1 (0.43) C5AR1TSHRHSD17B10ALDH1A1KDM4E
SCHEMBL5170283 0.95 TSHR (0.40) C5AR1TSHRHSD17B10ALDH1A1KDM4E
SCHEMBL5135547 0.93 C5AR1 (0.43) C5AR1TSHRHSD17B10ALDH1A1KDM4E
SCHEMBL5135633 0.90 C5AR1 (0.42) C5AR1TSHRHSD17B10ALDH1A1KDM4E
SCHEMBL5135042 0.90 C5AR1 (0.44) C5AR1TSHRHSD17B10ALDH1A1KDM4E
SCHEMBL5135121 0.88 C5AR1 (0.41) C5AR1TSHRHSD17B10ALDH1A1KDM4E
SCHEMBL5136154 0.88 C5AR1 (0.41) C5AR1TSHRHSD17B10ALDH1A1KDM4E
SCHEMBL5135025 0.88 C5AR1 (0.45) C5AR1TSHRHSD17B10ALDH1A1KDM4E
SCHEMBL5137095 0.86 C5AR1 (0.45) C5AR1TSHRHSD17B10ALDH1A1KDM4E
SCHEMBL5137962 0.86 C5AR1 (0.44) C5AR1TSHRHSD17B10ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed